12,372 trials
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESIs) — 69.4; 10.2; 17.2 percentage of participants
HIV-1 Infection
Primary: Percentage of Participants Receiving Doravirine/Islatravir (DOR/ISL) With ≥0.5 log10 Change From Day 1 Baseline to Day 8 in Human Immunodeficiency Virus Type 1 (HIV-1)…
Asthma
Primary: Change From Baseline in Weekly Average of Daily Trough (Predose and Pre-rescue Bronchodilator) Morning (AM) Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period…
Heart Failure With Reduced Ejection Fraction (HF-rEF)
Primary: Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints — 30; 28; 0; 0 Participants
Choroideremia
Primary: Percentage of Participants With a ≥15 -Letter Improvement From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 as Measured by the Early Treatment of Diabetic…
Psoriasis
Primary: Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 — 11.5; 33.1 percentage of participants — p=<0.0001
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1 — 25.5; 24.6; 21.5; 22.3 Percentage of participants
Amyloidosis
Primary: Percentage of Participants With Adverse Events (AEs) Leading to Study Discontinuation — 49.0; 16.8; 0.0 percentage of participants
Type 1 Diabetes Mellitus
Primary: Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%. — 41; 14; 22; 20…
Depressive Disorder, Major
Primary: Change From Baseline in the 17-item HAM-D Total Score at Day 15 — -12.3; -14.1 score on a scale — p=0.0141
Breast Cancer
Primary: Progression-free Survival in ESR1-mut Participants — 3.78; 1.87 months — p=0.0005
Diabetic Macular Edema (DME)
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 8 — 9.43; 8.85 letters
Coronary Artery Bypass Surgery · Postoperative Complications · Heart Failure
Primary: Postoperative Increase of Plasma NT-proBNP — 5390; 6452 ng/L — p=0.086
Osteoarthritis · Osteoarthritis, Knee
Primary: Change Form Baseline in WOMAC A Pain Subscale — -11.14; -11.82 cm — p=<0.025
Heart Failure
Primary: Left Ventricular Ejection Fraction — 44.7; 38.9; 44.9; 38.6 percentage of LVEF